Hostname: page-component-8448b6f56d-cfpbc Total loading time: 0 Render date: 2024-04-24T12:22:36.954Z Has data issue: false hasContentIssue false
  • English
  • Français

Switching atypical antipsychotics: a review

Published online by Cambridge University Press:  24 June 2014

Pierre Chue ,
Emmanuel Stip ,
Gary Remington  and
Lili Kopala
Pierre Chue*
Affiliation:
Department of Psychiatry, University of Alberta, Edmonton, Alberta, Canada
Emmanuel Stip
Affiliation:
Department of Psychiatry, University of Montreal, Montreal, Quebec, Canada
Gary Remington
Affiliation:
Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
Lili Kopala
Affiliation:
Department of Psychiatry, University of British Columbia, Vancouver, British Columbia, Canada
*
Dr Pierre Chue, 3rd Floor, 9942-108 Street, Edmonton, Alberta, Canada, T5K 2J5. Tel: +1 780 428 1776; Fax: +1 780 425 9317; E-mail: pchue@ualberta.ca
Get access Rights & Permissions [Opens in a new window]

Abstract

Background:

Atypical antipsychotics are increasingly used in the treatment of diverse psychiatric disorders; however, there is little information on the ‘why, when, and how’ of switching between the different atypical antipsychotics currently available.

Objective:

To review the data on switching and atypical antipsychotics.

Methods:

A literature search was initially conducted using the key words followed by a search of relevant articles including conference abstracts; relevant pharmaceutical companies were also contacted.

Results:

Clinical trial data are limited in terms of parameters measured, and case reports describe specific problems. Few studies are based on real world populations of psychiatric patients over the long-term. Careful patient and drug selections matched to a carefully supervised and appropriate cross titration based upon the pharmacodynamic and pharmacokinetic properties of all of the drugs involved is important to avoid potential complications such as re-emergence or worsening of psychosis and withdrawal, rebound, and emergent phenomena including new or uncovered side-effects. Psychoeducation and involvement of patients and caregivers in the process are also necessary for a successful switch.

Conclusion:

Despite the prevalence of switching in real world clinical practice, there is a paucity of data to guide clinicians with respect to effective and safe strategies. There are no criteria defining a successful switch. With the increasing range and formulations of atypical antipsychotics available, there is a rationale for their early use to avoid the practical problems associated with switching from conventional antipsychotics as well as the opportunity to maintain patients on an optimal atypical antipsychotic monotherapy.

Keywords

amisulpridearipiprazoleatypical antipsychoticsclozapineolanzapinequetiapinerisperidoneschizophreniaswitchingziprasidone
Type
Original Article
Information
Acta Neuropsychiatrica , Volume 16 , Issue 6 , December 2004 , pp. 301 - 313
Copyright
Copyright © 2004 Blackwell Munksgaard

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

National Institutefor Clinical Excellence (NICE). Schizophrenia: core interventions in the treatment and management of schizophrenia in primary and secondary care. National Collaborating Centre for Mental Health (NCCMH), 25th March 2003.Google Scholar
Volavka, J.Are medication-free periods necessary for phase 3 trials of new antipsychotic drugs? Arch Gen Psychiatry 1998;55: 280–283CrossRefGoogle ScholarPubMed
Williams, CL, Johnstone, BM, Kesterson, JG, Javor, KA, Schmetzer, AD.Evaluation of antipsychotic and concomitant medication use patterns in patients with schizophrenia. Med Care 1999;37: 81–86. CrossRefGoogle ScholarPubMed
Kinon, BJ, Basson, BR, Gilmore, JA, Malcolm, S, Stauffer, VL.Strategies for switching from conventional antipsychotic drugs or risperidone to olanzapine. J Clin Psychiatry 2000;61: 833–840. CrossRefGoogle ScholarPubMed
Voruganti, L, Cortese, L, Owyemi, Let al. Switching from conventional to novel antipsychotic drugs: results of a prospective naturalistic study. Schizophrenia Res 2002;57: 201–208. CrossRefGoogle ScholarPubMed
Amery, W, Marder, SR.Safety and switching issues of novel antipsychotics. Int J Psych Clin Practice 1998;2: S43–S49. Google Scholar
Kingsbury, SJ, Simpson, GM.Principles for starting, stopping, or switching medications. Psychiatric Services 2002;53: 1139–1140. CrossRefGoogle ScholarPubMed
Ganguli, R.Rationale and strategies for switching antipsychotics. Am J Health Syst Pharm 2002;59: S22–S26. CrossRefGoogle ScholarPubMed
Cook, PE, Goldberg, JO, Van Lieshout, RJ.Benefits of switching from typical to atypical antipsychotic medications: a longitudinal study in a community-based setting. Can J Psychiatry 2002;47: 870–874. CrossRefGoogle Scholar
Weiden, PJ, Aquila, R, Dalheim, L, Standard, JM.Switching antipsychotic medications. J Clin Psychiatry 1997;58: 63–72. Google ScholarPubMed
Masand, PS, Berry, SL.Switching antipsychotic therapies. Ann Pharmacotherapy 2000;34: 200–207. CrossRefGoogle ScholarPubMed
Taylor, D.Switching from typical to atypical antipsychotics. CNS Drugs 1997;8: 285–292. CrossRefGoogle Scholar
Peuskens, J.Switching approach in the management of schizophrenia patients. Int Clin Psychopharmacol 2000;15: S15–S19. Google ScholarPubMed
Burns, T, Chabannes, JP, Demyttenaere, K.Switching antipsychotic medications: general recommendations and switching to amisulpride. Curr Med Res Opin 2002;18: 201–208. CrossRefGoogle ScholarPubMed
Rafal, S, Tsuang, MT, Carpenter, WT.A dilemma born of progress: switching from clozapine to a newer antipsychotic. Am J Psychiatry 1999;156: 1086–1090. CrossRefGoogle ScholarPubMed
Bogan, AM, Shellhorn, E, Brown, ES, McDanald, C, Suppes, T.Switching outpatients between atypical antipsychotics. Prog Neuropsychopharmacol Biol Psychiatry 2000;24: 351–355. CrossRefGoogle ScholarPubMed
Bezchlibnyk-Butler, KZ, Jeffries, JJ, eds. Clinical Handbook of Psychotropic Drugs, 13th edn. Toronto, Canada: Hogrefe & Huber, 2003. Google Scholar
Meltzer, HY.Dimensions of outcome with clozapine. Br J Psychiatry 1992;160: 46–53. CrossRefGoogle Scholar
Canadian Pharmacists Association. Clozaril®. In: Compendium of Pharmaceuticals and Specialities. Toronto, Canada: Webcom Limited, 2003. Google Scholar
Meltzer, HY, Lee, MA, Ranjan, R, Mason, EA, Cola, PA.Relapse following clozapine withdrawal: effect of neuroleptic drugs and cyproheptadine. Psychopharmacol 1996;124: 176–187. CrossRefGoogle ScholarPubMed
Conley, RR.Optimizing treatment with clozapine. J Clin Psychiatry 1998;59: 44–48. Google ScholarPubMed
Aravagiri, M, Marder, SR, Van Putten, T, Midha, KK.Determination of risperidone in plasma by high-performance liquid chromatography with electrochemical detection: application to therapeutic drug monitoring in schizophrenic patients. J Pharmaceut Sci 1993;82: 447–449. CrossRefGoogle ScholarPubMed
Coates, J.Urinary detection of olanzapine – an aid to compliance. Br J Psychiatry 1999;175: 591–592. CrossRefGoogle ScholarPubMed
Green, A.Predictors of response to clozapine. J Clin Psychiatry 1996;14: 25–26. Google Scholar
Atkin, K, Kendall, F, Gould, D, Freeman, H, Liberman, J, O'Sullivan, D.Neutropenia and agranulocytosis in patients receiving clozapine in the UK and Ireland. Br J Psychiatry 1996;169: 483–488. CrossRefGoogle ScholarPubMed
Prior, T, Baker, G.Interactions between the cytochrome P450 system and the second-generation antipsychotics. J Psychiatry Neurosci 2003;28: 99–112. Google ScholarPubMed
Baldessarini, R, Gardner, D, Garver, D.Conversions from clozapine to other antipsychotic drugs. Arch Gen Psychiatry 1996;52: 1071–1072. Google Scholar
Bobba, R, Carr, A.Severe extrapyramidal side effects when discontinuing clozapine and starting haloperidol. Can J Psychiatry 1997;42: 530. CrossRefGoogle ScholarPubMed
Friedman, JH, Goldstein, S, Jacques, C.Substituting clozapine for olanzapine in psychiatrically Parkinson's disease patients: results of an open label pilot study. Clin Neuropharmacol 1998;21: 285–288. Google ScholarPubMed
Fernandez, HH, Lannon, MC, Friedman, JH, Abbott, BP.Clozapine replacement by quetiapine for the treatment of drug-induced psychosis in Parkinson's disease. Mov Disord 2000;15: 579–581. 3.0.CO;2-0>CrossRefGoogle ScholarPubMed
Shore, D.Clinical implications of clozapine discontinuation: report of an NIMH workshop. Schizophr Bull 1995;21: 333–338. CrossRefGoogle ScholarPubMed
Lee, JW, Robertson, S.Clozapine withdrawal catatonia and neuroleptic malignant syndrome: a case report. Ann Clin Psychiatry 1997;9: 165–169. CrossRefGoogle ScholarPubMed
Llorca, PM, Penault, F, Lancon, C, Dufumier, E, Vaiva, G.The concept of supersensitivity psychosis. The particular case of clozapine. Encephale 1999;25: 638–644. Google ScholarPubMed
Szafranski, T, Gmurkowski, K.Clozapine withdrawal. A Review. Psychiatr Pol 1999;33: 51–67. Google ScholarPubMed
Gupta, S, Daniel, DG.Cautions in the clozapine-to-risperidone switch. Ann Clin Psychiatry 1995;7: 149. CrossRefGoogle ScholarPubMed
Delassus-Guenault, N, Jegouzo, A, Odou, Pet al. Clozapine-olanzapine: a potentially dangerous switch. A report of two cases. J Clin Pharm Ther 1999;24: 191–195. CrossRefGoogle ScholarPubMed
Onofrj, M, Thomas, A, Bonanni, L, Iacono, D, Gambi, F.Leucopenia induced by low dose clozapine in Parkinson's disease recedes shortly after drug withdrawal. Clinical case descriptions with commentary on switch-over to olanzapine. Neurol Sci 2000;21: 209–215. CrossRefGoogle ScholarPubMed
De Leon, J, Stanilla, JK, White, AO, Simpson, GM.Anticholinergics to treat clozapine withdrawal. J Clin Psychiatry 1994;55: 119–120. Google ScholarPubMed
Koreen, AR, Lieberman, JA, Kronig, M, Cooper, TB.Cross-tapering clozapine and risperidone. Am J Psychiatry 1995;152: 1690. Google ScholarPubMed
Benedetti, F, Cavallaro, R, Smeraldi, E.Olanzapine-induced neutropenia after clozapine-induced neutropenia. Lancet 1999;354: 567. CrossRefGoogle ScholarPubMed
Diaz, P, Hogan, TP.Granulocytopenia with clozapine and quetiapine. Am J Psychiatry 2001;158: 651. CrossRefGoogle ScholarPubMed
Godleski, LS, Sernyak, MJ.Agranulocytosis after addition of risperidone to clozapine treatment. Am J Psychiatry 1996;153: 735–736. Google ScholarPubMed
Bacher, NM, Kaup, BA.Combining risperidone with standard neuroleptics for refractory schizophrenic patients. Am J Psychiatry 1996;153: 137. Google ScholarPubMed
Radford, J, Brown, T, Borison, R.Unexpected dystonia while changing from clozapine to risperidone. J Clin Psychopharmacol 1995;15: 225–226. CrossRefGoogle ScholarPubMed
Ekblom, B, Eriksson, K, Lindstrom, LH.Super-sensitivity psychosis in schizophrenic patients after sudden clozapine withdrawal. Psychopharmacology 1984;83: 293–294. CrossRefGoogle Scholar
Dickson, R, Williams, R, Dalby, JT.Dystonic reactions and relapse with clozapine discontinuation and risperidone initiation. Can J Psychiatry 1994;39: 184. CrossRefGoogle Scholar
Borison, RL, Consensus Study Group on Risperidone Dosing. Changing antipsychotic medication; guidelines on the transition to treatment with risperidone. Clin Therapeutics 1996;18: 592–607. CrossRefGoogle ScholarPubMed
Still, DJ, Dorson, PG, Crismon, ML, Pousson, C.Effects of switching inpatients with treatment resistant schizophrenia from clozapine to risperidone. Psychiatr Serv 1996;47: 1382–1384. Google ScholarPubMed
Kopala, LC.Clinical experience in developing treatment regimens with the novel antipsychotic risperidone. Int Clin Psychopharmacol 1997;12: S11–S18. CrossRefGoogle ScholarPubMed
Zimbroff, DL.Switching patients from clozapine to risperidone therapy. Am J Psychiatry 1995; 152: 1102. Google ScholarPubMed
Horne, RL, Miller, F. Outcome in patients switched from clozapine to risperidone. Poster NR447. Presented at 148th Ann Meet Am Psychiatric Assoc, May 20–25 1995, Miami, USA.Google Scholar
Lane, HY, Chiu, WC, Chou, JC, Wu, ST, Su, MH, Chang, WH.Risperidone in acutely exacerbated schizophrenia: dosing strategies and plasma levels. J Clin Psychiatry 2000;61: 209–214. CrossRefGoogle ScholarPubMed
Feifel, D, Moutier, CY, Perry, W.Safety and tolerability of a rapidly escalating dose-loading regimen for risperidone. J Clin Psychiatry 2000;61: 909–911. CrossRefGoogle ScholarPubMed
Mauri, MC, Laini, V, Boscati, Let al. Long-term treatment of chronic schizophrenia with risperidone: a study with plasma levels. Eur Psychiatry 2001;16: 57–63. CrossRefGoogle ScholarPubMed
Wirshing, WC, Marder, SR.Efficacy and dosing issues of novel antipsychotics. Int J Psychiatry Clin Practice 1998;2: S35–S38. Google Scholar
Canadian Pharmacists Association. Risperdal®. In: Compendium of Pharmaceuticals and Specialities. Toronto, Canada: Webcom Limited, 2003. Google Scholar
Williams, RW.Optimal dosing with risperidone: updated recommendations. J Clin Psychiatry 2001;62: 282–289. CrossRefGoogle ScholarPubMed
Desai, NM, Huq, Z, Martin, SD, McDonald, G, Schizophrenia Treatment and Assessment Group. Switching from depot antipsychotics to risperidone: results of a study of chronic schizophrenia. Advan Ther 1999;16: 78–88. Google ScholarPubMed
Bennie, EH.High-dose antipsychotic medication. Br J Psychiatry 1994;165: 553. CrossRefGoogle ScholarPubMed
Kirov, GK, Murray, RM, Seth, RV, Feeney, S.Observations on switching patients with schizophrenia to risperidone treatment. Acta Psychiatr Scand 1997;95: 439–443. CrossRefGoogle ScholarPubMed
Scordo, MG, Spina, E, Facciola, G, Avenoso, A, Johansson, I, Dahl, M-L.Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone. Psychopharmacology 1999;147: 300–305. CrossRefGoogle ScholarPubMed
Darby, JK, Pasta, DJ, Elfand, L, Dabiri, L, Clark, L, Herbert, J.Risperidone dose and blood level variability: accumulation effects and interindividual and intraindividual variability in the nonresponder patient in the clinical setting. J Clin Psychopharmacol 1997;17: 478–484. CrossRefGoogle Scholar
Yanagida, H, Morokawa, Y, Ohki, Met al. Rate of metabolism of risperidone and the ratio of anti-5-HT2A to anti-D2 activity in plasma. Presented at XXII CNIP Congress, 9–13 July 2000, Brussels, Belgium.Google Scholar
Yoshimura, R, Nakamura, J, Ueda, N, Terao, T.Effect of risperidone on plasma free 3-methoxy-4-hydroxyphenylglycol (pMHPG) levels in schizophrenic patients: relationship among plasma concentrations of risperidone and 9-hydroxyrisperidone, pMHPG levels, and clinical improvement. Int Clin Psychopharmacol 2000;15: 175–180. CrossRefGoogle ScholarPubMed
Spina, E, Avenoso, A, Facciola, Get al. Plasma concentrations of risperidone and 9-hydroxyrisperidone: effect of comedication with carbamazepine or valproate. Therapeutic Drug Monitoring 2000;22: 481–485. CrossRefGoogle ScholarPubMed
Frackiewicz, EJ, Herrera, JM, Sramek, JJ, Collazo, Y, Lawson, WB.Risperidone in the treatment of Hispanic inpatients with schizophrenia: a pilot study. Psychiatry 2002;65: 371–374. CrossRefGoogle ScholarPubMed
Gardner, DM, Baldessarini, RJ, Benzo, J, Zarate, CA Jr, Tohen, M.Switching between clozapine and risperidone treatment. Can J Psychiatry 1997;42: 430–431. CrossRefGoogle ScholarPubMed
Mok, H, Yatham, LN.Response to clozapine as a predictor of risperidone response in schizophrenia. Am J Psychiatry 1994;151: 1393–1394. Google ScholarPubMed
Cutler, AJ, Goldstein, JM, Tumas, JA.Dosing and switching strategies for quetiapine fumarate. Clin Therapeutics 2002;24: 209–222. CrossRefGoogle ScholarPubMed
Goldstein, JM. Safety and tolerability of switching from conventional antipsychotic therapy to seroquel (quetiapine fumarate) followed by abrupt withdrawal from seroquel. Presented at 151st Ann Meet American Psychiatric Association, 30 May−4 June 1998, Toronto, Canada.Google Scholar
Devane, CL, Nemeroff, CB.Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. Clin Pharmacokinet 2001;40: 509–522. CrossRefGoogle ScholarPubMed
Lee, CT, Conde, BJ, Mazlan, Met al. Switching to olanzapine from previous antipsychotics: a regional collaborative multicenter trial assessing 2 switching techniques in Asia Pacific. J Clin Psychiatry 2002;63: 569–576. CrossRefGoogle ScholarPubMed
Labelle, A, Bourget, D, Boulay, LJ, Ellis, J, Tessier, P.Switching outpatients with schizophrenia and related disorders on long-acting injectable antipsychotics to olanzapine: an open-label naturalistic pilot study. J Clin Psychopharmacol 2002;22: 545–553. CrossRefGoogle ScholarPubMed
Littrell, KH, Peabody, C, Johnson, Cet al. Patients switched from depot antipsychotics to risperidone or olanzapine: an open-label randomized trial. Poster NR551. Presented at 152nd Ann Meet Am Psych Assocn, May 15–19 1999, Washington, DC.Google Scholar
Godleski, LS, Goldsmith, J, Vieweg, WV, Zettwoch, NC, Stikovac, DM, Lewis, SJ.Switching from depot antipsychotic drugs to olanzapine in patients with chronic schizophrenia. J Clin Psychiatry 2003;62: 119–122. CrossRefGoogle Scholar
Henderson, DC, Nasrallah, RA, Goff, DC.Switching from clozapine to olanzapine in treatment-refractory schizophrenia: safety, clinical efficacy, and predictors of response. J Clin Psychiatry 1998;59: 585–588. CrossRefGoogle ScholarPubMed
Littrell, KH, Johnson, CG, Hilligoss, NM, Peabody, CD, Littrell, SH.Switching clozapine responders to olanzapine. J Clin Psychiatry 2000;61: 912–915. CrossRefGoogle ScholarPubMed
Tollefson, GD, Dellva, MA, Mattler, CA, Kane, JM, Wirshing, DA, Kinon, BJ.Controlled, double-blind investigation of the clozapine discontinuation symptoms with conversion to either olanzapine or placebo. J Clin Psychopharmacol 1999;19: 435–443. CrossRefGoogle ScholarPubMed
Canadian Pharmacists Association. Zyprexa®. In: Compendium of Pharmaceuticals and Specialities. Toronto, Canada: Webcom Limited, 2003. Google Scholar
Weiden, PJ, Simpson, GM, Potkin, SG, O'Sullivan, RL.Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia. J Clin Psychiatry 2003;64: 580–588. CrossRefGoogle ScholarPubMed
Kingsbury, SJ, Fayek, M, Trufasiu, D, Zada, J, Simpson, GM.The apparent effects of ziprasidone on plasma lipids and glucose. J Clin Psychiatry 2001;62: 347–349. CrossRefGoogle ScholarPubMed
Beedham, C, Miceli, JJ, Obach, RS.Ziprasidone metabolism, aldehyde oxidase, and clinical implications. J Clin Psychopharmacol 2003;23: 229–232. CrossRefGoogle ScholarPubMed
Casey, DE, Carson, WH, Saha, AR, Liebeskind, A, Ali, MW, Jody, D, Ingenito, GG.Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study. Psychopharmacol (Berl) 2003;166: 391–399. CrossRefGoogle ScholarPubMed
Bowles, TM, Levin, GM.Aripiprazole: a new atypical antipsychotic drug. Ann Pharmacother 2003;37: 687–694. CrossRefGoogle ScholarPubMed
Peuskens, J.Switching to amisulpride. Curr Med Res Opin 2002;18: S23–S28. CrossRefGoogle ScholarPubMed
Lecrubier, Y, Azorin, M, Bottai, Tet al. Consensus on the practical use of amisulpride, an atypical antipsychotic, in the treatment of schizophrenia. Neuro-psychobiology 2001;44: 41–46. Google ScholarPubMed
Yagdiran, O, Haasen, C, Nika, E, Krausz, M, Naber, D.Switching to amisulpride due to hepatic complications. Eur Psychiatry 2002;17: 170–171. CrossRefGoogle ScholarPubMed
Jatzko, A, Ries, S, Schreiner, A, Braus, DF.Acute tongue and pharyngeal spasms during changeover from clozapine to amisulpride. A case example. Nervenarzt 2000;71: 919–922. CrossRefGoogle ScholarPubMed
Lambert, T. Practical issues in switching to novel antipsychotics. Presented at the XXII CINP Congress, 9th−13th July 2000, Brussels, Belgium.Google Scholar
Nayudu, SK, Scheftner, WA.Case report of withdrawal syndrome after olanzapine discontinuation. J Clin Psychopharmacol 2000;20: 489–490. CrossRefGoogle ScholarPubMed
Anand, VS, Dewan, MJ.Withdrawal-emergent dyskinesia in a patient on risperidone undergoing dosage reduction. Ann Clin Psychiatry 1996;8: 179–182. CrossRefGoogle Scholar
Gilbert, PL, Harris, MJ, McAdams, LA, Jeste, DV.Neuroleptic withdrawal in schizophrenic patients. A review of the literature. Arch Gen Psychiatry 1995;52: 173–188. CrossRefGoogle ScholarPubMed
Verghese, C, Deleon, J, Nair, C, Simpson, G.Clozapine withdrawal effects and receptor profiles of typical and atypical neuroleptics. Biol Psychiatry 1996;39: 135–138. CrossRefGoogle ScholarPubMed
Jeste, DV, Rockwell, E, Harris, MJ, Lohr, JB, Lacro, J.Conventional versus newer antipsychotics in elderly patients. Am J Geriatric Psychiatry 1991;7: 70–76. CrossRefGoogle Scholar
Barak, Y, Shamir, E, Weizman, R.Would a switch from typical antipsychotics to risperidone be beneficial for elderly schizophrenic patients? A naturalistic, long-term, retrospective comparative study. J Clin Psychopharmacol 2002;22: 115–120. CrossRefGoogle ScholarPubMed
Malla, AK, Norman, RM, Kotteda, V, Zirul, S.Switching from therapy with typical antipsychotic agents to risperidone: long term impact on patient outcome. Clin Ther 1999;21: 806–817. CrossRefGoogle ScholarPubMed
Conlon, L, Fahy, TJO, Toole, R, Gilligan, J, Prescott, P.Risperidone in chronic schizophrenia: a detailed audit, open switch study and two-year follow up of patients on depot medication. Eur Psychiatry 2002;17: 459–465. CrossRefGoogle ScholarPubMed
Fleischhacker, WW, Eerdekens, M, Karcher, Ket al. Treatment of schizophrenia with long-acting risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. J Clin Psychiatry 2003;64: 1250–1257. CrossRefGoogle ScholarPubMed
Jann, MW.Clinical significance of drug binding, protein binding, and binding displacement drug interactions. Psychopharmacol Bull 2002;36: 22–41. Google ScholarPubMed
Weiden, PJ, Aquila, R, Emanuel, M, Zygmunt, A.Long-term considerations after switching antipsychotics. J Clin Psychiatry 1998;59: 36–49. Google ScholarPubMed
Altamura, AC, Sassella, F, Santini, A, Montresor, C, Fumagalli, S, Mundo, E.Intramuscular preparations of antipsychotics: uses and relevance in clinical practice. Drugs 2003;63: 493–512. CrossRefGoogle ScholarPubMed